Natan Ponieman

On Friday, the Royal College of Psychiatrists has published a new report assessing the safety and efficacy of psychedelics and related substances as treatments for mental illness.

Professor David Nutt stands out as a leading figure in modern psychedelic science, tirelessly pushing the boundaries of how drugs such as psilocybin, MDMA, LSD, DMT, and ketamine, are understood, regulated, and used in therapy.

For the first time, data from real-world application of psilocybin treatment under a regulated program was published by one of the Oregon clinics providing treatment.

Dr. Celia Morgan is one of the UK's leading figures in ketamine and psychedelic research, especially in the domain of addiction and mental health.

On 4 December 2025, London's Conway Hall will host the third PSYCH Symposium, bringing together leaders across science, policy, investment and clinical medicine to chart the next phase of psychedelic healthcare in Europe.

A new study in The Journal of Neuroscience has shed light on how the psychedelic N,N-Dimethyltryptamine, or DMT, changes brain activity during its most intense psychological effects.

Psilocybin continues to gain momentum as a possible alternative to mental health treatments that leave large numbers of patients without recovery.

The third edition of PSYCH Symposium, held on December 4 at London's Conway Hall, reflected a field in transition. While much of the day focused on clinical progress and regulatory momentum, several panels moved beyond efficacy to confront harder questions.

In 2025, the psychedelic medicine sector reached a more defined phase of maturity, as Big Pharma entry, late-stage clinical readouts, and incremental

Japanese pharma company Otsuka Pharmaceutical announced its acquisition of Transcend Therapeutics, Inc., a New York-based biotech company, through Otsuka's wholly-owned American subsidiary.